19.76

7.92% -1.71

Nurix Therapeutics Inc (NRIX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$21.47

Offen:

$21.43

24-Stunden-Volumen:

1.64M

Relative Volume:

1.04

Marktkapitalisierung:

$2.00B

Einnahmen:

$54.55M

Nettoeinkommen (Verlust:

$-193.57M

KGV:

-6.8374

EPS:

-2.89

Netto-Cashflow:

$-181.86M

1W Leistung:

+20.92%

1M Leistung:

+60.60%

6M Leistung:

+57.66%

1J Leistung:

-4.31%

1-Tages-Spanne:

$19.73

$21.99

1-Wochen-Bereich:

$16.25

$22.50

52-Wochen-Spanne:

$8.18

$22.95

Nurix Therapeutics Inc Stock (NRIX) Company Profile

Firmenname

Nurix Therapeutics Inc

Sektor

Healthcare (1139)

Branche

Biotechnology (634)

Telefon

(415) 660-5320

Adresse

1700 OWENS STREET, SUITE 205, SAN FRANCISCO

Mitarbeiter

286

Twitter

Nächster Verdiensttermin

2025-10-09

Neueste SEC-Einreichungen

NRIX's Discussions on Twitter

Vergleichen Sie NRIX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NRIX Nurix Therapeutics Inc	19.77	2.18B	54.55M	-193.57M	-181.86M	-2.89
VRTX Vertex Pharmaceuticals Inc	438.54	112.15B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	700.32	73.91B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	417.88	56.81B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	892.74	55.46B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	193.73	41.92B	447.02M	-1.18B	-906.14M	-6.1812

Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-11-24	Fortgesetzt	Truist	Buy
2025-10-21	Eingeleitet	Mizuho	Outperform
2025-03-17	Eingeleitet	Leerink Partners	Market Perform
2024-12-10	Eingeleitet	BTIG Research	Buy
2024-12-06	Eingeleitet	BMO Capital Markets	Outperform
2024-10-24	Eingeleitet	UBS	Buy
2024-10-11	Eingeleitet	Jefferies	Buy
2024-09-06	Fortgesetzt	Robert W. Baird	Outperform
2024-07-31	Eingeleitet	Truist	Buy
2023-06-26	Fortgesetzt	Oppenheimer	Outperform
2023-03-09	Eingeleitet	Barclays	Overweight
2023-02-28	Eingeleitet	Oppenheimer	Outperform
2022-10-11	Eingeleitet	Morgan Stanley	Equal-Weight
2022-05-31	Hochstufung	Wells Fargo	Equal Weight → Overweight
2022-02-10	Eingeleitet	Wells Fargo	Equal Weight
2021-12-29	Eingeleitet	H.C. Wainwright	Buy
2021-10-14	Eingeleitet	SVB Leerink	Outperform
2021-06-04	Fortgesetzt	Robert W. Baird	Outperform
2021-04-30	Fortgesetzt	Piper Sandler	Overweight
2021-04-30	Eingeleitet	RBC Capital Mkts	Outperform
2021-04-14	Eingeleitet	Berenberg	Buy
2020-11-19	Eingeleitet	Robert W. Baird	Outperform
2020-08-18	Eingeleitet	JP Morgan	Overweight
2020-08-18	Eingeleitet	Needham	Buy
2020-08-18	Eingeleitet	Piper Sandler	Overweight
2020-08-18	Eingeleitet	Stifel	Buy

Alle ansehen

Nurix Therapeutics Inc Aktie (NRIX) Neueste Nachrichten

02:34 AM

NRIX Analyst Rating Update: BTIG Raises Price Target | NRIX Stoc - GuruFocus

02:34 AM

02:27 AM

Nurix (NRIX) Soars 18.7% on Encouraging Blood Cancer Treatment Trial - Insider Monkey

02:27 AM

06:25 AM

NRIX: Bexobrutideg achieved a 75% response rate with durable, well-tolerated outcomes in Waldenström macroglobulinemia - TradingView

06:25 AM

06:13 AM

Nurix Therapeutics Presents New Clinical Data at ASH Annual Meeting - TradingView

06:13 AM

Dec 08, 2025

Nurix reports 75% response rate for bexobrutideg in WM patients By Investing.com - Investing.com Australia

Dec 08, 2025

Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg in Waldenström Macroglobulinemia at the 67th American Society of Hematology Annual Meeting and Exposition - Investing News Network

Dec 08, 2025

Nurix reports 75% response rate for bexobrutideg in WM patients - Investing.com

Dec 08, 2025

NRIX Clinical Trial Data Highlights Promising Results for Bexobr - GuruFocus

Dec 08, 2025

Nurix Therapeutics (NASDAQ:NRIX) Earns Buy Rating from Needham & Company LLC - MarketBeat

Dec 08, 2025

Nurix Therapeutics Reports 75% Objective Response Rate for Bexobrutideg in Heavily Pre-treated Waldenström Macroglobulinemia Patients at ASH Annual Meeting - Quiver Quantitative

Dec 08, 2025

Nurix Therapeutics presents new data from the phase 1 trial of bexobrutideg in Waldenström macroglobulinemia at the 67th American Society of Hematology annual meeting and exposition - marketscreener.com

Dec 08, 2025

Nurix Therapeutics (Nasdaq: NRIX) posts 75% ORR in Phase 1 WM study; PFS, DOR not reached - Stock Titan

Dec 08, 2025

Nurix Therapeutics (NRIX): Analyst Reiterates Buy Rating, Mainta - GuruFocus

Dec 08, 2025

Dec 07, 2025

NRIX Shows Promising Results in Phase 1a/1b Clinical Trial for B - GuruFocus

Dec 07, 2025

Bollard Group LLC Makes New $1.40 Million Investment in Nurix Therapeutics, Inc. $NRIX - MarketBeat

Dec 07, 2025

Dec 06, 2025

Nurix reports 83% response rate for bexobrutideg in CLL patients - Investing.com

Dec 06, 2025

Nurix Therapeutics Reports Promising Phase 1a/1b Clinical Data for Bexobrutideg in Patients with Relapsed or Refractory CLL, Showcasing 83% Objective Response Rate and 22.1 Months Median Progression-Free Survival - Quiver Quantitative

Dec 06, 2025

Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (AS - Stock Titan

Dec 06, 2025

Affinity Asset Advisors LLC Increases Stock Holdings in Nurix Therapeutics, Inc. $NRIX - MarketBeat

Dec 06, 2025

Dec 04, 2025

Is Nurix Therapeutics Inc. stock positioned for long term growthPortfolio Risk Summary & Low Drawdown Trading Techniques - Newser

Dec 04, 2025

Dec 03, 2025

In the Wake of Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Latest US$86m Market Cap Drop, Institutional Owners May Be Forced to Take Severe Actions - 富途牛牛

Dec 03, 2025

Dec 02, 2025

Nurix Therapeutics (NRIX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga

Dec 02, 2025

Nurix Therapeutics (NRIX): Assessing Valuation as Investors Await Key NX-5948 Clinical Data Webcast - Yahoo Finance

Dec 02, 2025

What is the fair value of Nurix Therapeutics Inc. stock now - Newser

Dec 02, 2025

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Dec 02, 2025

Is the Upcoming NX-5948 Clinical Data Update Shaping the Investment Case for Nurix Therapeutics (NRIX)? - simplywall.st

Dec 02, 2025

Nurix to host webcast on bexobrutideg clinical data next week By Investing.com - Investing.com Canada

Dec 02, 2025

Dec 01, 2025

Nurix to host webcast on bexobrutideg clinical data next week - Investing.com

Dec 01, 2025

Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition - The Manila Times

Dec 01, 2025

Nurix Therapeutics to Host Webcast on Clinical Data for Bexobrutideg in CLL and WM on December 8, 2025 - Quiver Quantitative

Dec 01, 2025

Nurix Therapeutics (Nasdaq: NRIX) to host Dec. 8 webcast on Phase 1 bexobrutideg CLL data - Stock Titan

Dec 01, 2025

Geode Capital Management LLC Purchases 157,592 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat

Dec 01, 2025

Layoff Tracker: Valneva Terminates 30 Amid Site Closure - BioSpace

Dec 01, 2025

Nov 30, 2025